← Browse by Condition
Medical Condition

friedreich ataxia

Total Trials
5
Recruiting Now
5
Trial Phases
Phase 2, Phase 1

ClinicalMetric tracks all active clinical trials for friedreich ataxia sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — friedreich ataxia Clinical Trials

How many clinical trials are currently recruiting for friedreich ataxia?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for friedreich ataxia, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for friedreich ataxia?
friedreich ataxia research spans Phase 1 (1 trial), Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a friedreich ataxia clinical trial?
Eligibility criteria for friedreich ataxia trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
1
Top Sponsors
Larimar Therapeutics, Inc. 1 trial
Weill Medical College of Cornell University 1 trial
Lexeo Therapeutics 1 trial
Centre Hospitalier Universitaire de Nice 1 trial
Biogen 1 trial

Recruiting Clinical Trials

NCT06447025 Phase 2
Recruiting
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
Enrollment
85 pts
Location
United States
Sponsor
Larimar Therapeutics, Inc.
View Trial →
NCT05302271 Phase 1
Recruiting
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
Enrollment
25 pts
Location
United States
Sponsor
Weill Medical College of Corne...
View Trial →
NCT06865482
Recruiting
Clinical Course Of Disease In Participants With FA-CM
Enrollment
65 pts
Location
United States, Brazi...
Sponsor
Lexeo Therapeutics
View Trial →
NCT07013292
Recruiting
Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
Enrollment
40 pts
Location
France
Sponsor
Centre Hospitalier Universitai...
View Trial →
NCT06628687
Recruiting
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
Enrollment
10 pts
Location
United States
Sponsor
Biogen
View Trial →

Related Conditions

cardiomyopathies (1) cardiac hypertrophy (1) myocardial fibrosis (1) cardiomyopathy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology